Inhibiting CSF1R not only blocks TAM recruitment but also skews M2 to M1 phenotype, which effectively resulted in retarded tumor growth, inducing cytotoxic T-cell response and better prognosis with combinatorial chemotherapy (219). This evidence concerns the gene CSF1R and neoplasm.